Acromegaly Is Poor Setting For Symptom Claim, FDA Somatuline Review Finds
This article was originally published in Pharmaceutical Approvals Monthly
Ipsen could not support extension of acromegaly therapy indications past biochemical endpoints to include clinical symptom claims, according to FDA’s review of the European firm’s Somatuline Depot (lanreotide prolonged-release injection).
You may also be interested in...
Behind The Approval Letter: A Year Of Drug Review Profiles
FDA reviewers stuck to established assessment practices during the coronavirus crisis and produced one of the agency’s largest yearly novel approval counts ever.
Spironolactone TOPCAT Regional Analysis Falls Short At US FDA AdComm, But Hospitalizations Drive Vote
A new indication for the generic diuretic in heart failure with preserved ejection fraction gets an 8-4 vote, with one abstention, despite troubles an analysis that tries to revive the TOPCAT trial with an analysis excluding Eastern European sites – or about half the participants.